Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy

Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy

Author Medrano, Ruan Felipe Vieira Google Scholar
Catani, Joao Paulo Portela Google Scholar
Ribeiro, Aline Hunger Google Scholar
Tomaz, Samanta Lopes Autor UNIFESP Google Scholar
Merkel, Christian A. Google Scholar
Costanzi-Strauss, Eugenia Google Scholar
Strauss, Bryan E. Google Scholar
Abstract Previously, we combined p19(Arf) (Cdkn2a, tumor suppressor protein) and interferon beta (IFN-beta, immunomodulatory cytokine) gene transfer in order to enhance cell death in a murine model of melanoma. Here, we present evidence of the immune response induced when B16 cells succumbing to death due to treatment with p19(Arf) and IFN-beta are applied in vaccine models. Use of dying cells for prophylactic vaccination was investigated, identifying conditions for tumor-free survival. After combined p19(Arf) and IFN-beta treatment, we observed immune rejection at the vaccine site in immune competent and nude mice with normal NK activity, but not in NOD-SCID and dexamethasone immunosuppressed mice (NK deficient). Combined treatment induced IL-15, ULBP1, FAS/APO1 and KILLER/DR5 expression, providing a mechanism for NK activation. Prophylactic vaccination protected against tumor challenge, where markedly delayed progression and leukocyte infiltration were observed. Analysis of primed lymphocytes revealed secretion of TH1-related cytokines and depletion protocols showed that both CD4(+) and CD8(+) T lymphocytes are necessary for immune protection. However, application of this prophylactic vaccine where cells were treated either with IFN-beta alone or combined with p19(Arf) conferred similar immune protection and cytokine activation, yet only the combination was associated with increased overall survival. In a therapeutic vaccine protocol, only the combination was associated with reduced tumor progression. Our results indicate that by harnessing cell death in an immunogenic context, our p19(Arf) and IFN-beta combination offers a clear advantage when both genes are included in the vaccine and warrants further development as a novel immunotherapy for melanoma.
Keywords Cell death
p19Arf
Interferon beta
Immunotherapy
Melanoma
Adenovirus
xmlui.dri2xhtml.METS-1.0.item-coverage New York
Language English
Sponsor Sao Paulo Research Foundation
Grant number FAPESP: 13/25167-5
FAPESP: 11/50911-4
FAPESP: 13/09474-5
FAPESP: 11/10656-5
FAPESP: 14/11524-3
Date 2016
Published in Cancer Immunology Immunotherapy. New York, v. 65, n. 4, p. 371-382, 2016.
ISSN 0340-7004 (Sherpa/Romeo, impact factor)
Publisher Springer
Extent 371-382
Origin http://dx.doi.org/10.1007/s00262-016-1807-8
Access rights Closed access
Type Article
Web of Science ID WOS:000373952700002
URI https://repositorio.unifesp.br/handle/11600/56126

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account